Literature DB >> 20180821

The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by alpha-macroglobulin-thrombin.

R J Wagenvoord1, J Deinum, M Elg, H C Hemker.   

Abstract

BACKGROUND: Thrombin generation (TG) in plasma can be monitored continuously with a fluorogenic thrombin substrate using calibrated automated thrombinography (CAT). In the presence of low concentrations of a reversible direct thrombin inhibitor (DTI), CAT shows an unexpected effect: the endogenous thrombin potential (ETP) increases at low concentrations of the inhibitor to subsequently decrease concentration dependently at higher concentrations (> approximately 100 nm).
OBJECTIVES: To find an explanation for this phenomenon, we measured the concentrations of free thrombin and alpha(2)-macroglobulin-thrombin complex (alpha(2)MT) with a sub-sampling technique in the presence of AR-H067637, a selective DTI.
RESULTS: At all concentrations of the DTI there was a gradual dose-dependent decrease in the concentration of free, not-inhibited thrombin but a transient increase in free alpha(2)MT due to competition of thrombin and alpha(2)MT for the inhibitor. Because the CAT technique uses an algorithm to subtract alpha(2)MT activity from the total amidolytic activity, this transient increase in alpha(2)MT activity is not subtracted and erroneously attributed to thrombin itself.
CONCLUSIONS: This study explains the spurious increase in ETP observed at low DTI concentrations. The results obtained in plasma were corroborated by observations in a thrombin generating system reconstituted with purified factors. In practise, the effect of DTIs on TG can be reliably evaluated from the area under the curve till time-to-peak.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20180821     DOI: 10.1111/j.1538-7836.2010.03822.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  10 in total

1.  Exposure-response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.

Authors:  Gregory Y H Lip; Lars H Rasmussen; S Bertil Olsson; Eva Jensen; Bengt Hamrén; Ulf G Eriksson; Karin Wåhlander
Journal:  Br J Clin Pharmacol       Date:  2015-09-22       Impact factor: 4.335

2.  Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study.

Authors:  Meyer Michel Samama; Céline Guinet; Léna Le Flem; Emmanuel Ninin; Jean-Marc Debue
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

3.  Thrombin Generation in Vitreous and Subretinal Fluid of Patients with Retinal Detachment.

Authors:  Verena C Mulder; Jeroen Bastiaans; Cornelis J M van Leuven; Jan C van Meurs; Cornelis Kluft
Journal:  Ophthalmologica       Date:  2018-04-04       Impact factor: 3.250

4.  Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo.

Authors:  E Perzborn; S Heitmeier; U Buetehorn; V Laux
Journal:  J Thromb Haemost       Date:  2014-06-19       Impact factor: 5.824

5.  Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation: A Noninterventional Study.

Authors:  Argirios E Tsantes; Elias Kyriakou; Ignatios Ikonomidis; Konstantinos Katogiannis; Ioannis Papadakis; Panagiota Douramani; Petros Kopterides; Violetta Kapsimali; John Lekakis; Iraklis Tsangaris; Stefanos Bonovas
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

6.  The Comparison of Therapeutic Efficacy Between Dabigatran Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation.

Authors:  Hongxia Li; Lei Zhang; Ming Xia; Chi Zhang; Tingbo Jiang
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

7.  Global assays and the management of oral anticoagulation.

Authors:  Herm Jan M Brinkman
Journal:  Thromb J       Date:  2015-02-10

8.  The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency.

Authors:  Irina V Gribkova; Elena N Lipets; Irina G Rekhtina; Alex I Bernakevich; Dorzho B Ayusheev; Ruzanna A Ovsepyan; Fazoil I Ataullakhanov; Elena I Sinauridze
Journal:  Sci Rep       Date:  2016-07-05       Impact factor: 4.379

9.  A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability.

Authors:  Oliver Königsbrügge; Silvia Koder; Julia Riedl; Simon Panzer; Ingrid Pabinger; Cihan Ay
Journal:  Clin Exp Med       Date:  2016-04-19       Impact factor: 3.984

10.  Comparison of antithrombin-dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots.

Authors:  Stella Salta; Loula Papageorgiou; Annette K Larsen; Patrick Van Dreden; Claire Soulier; Dennis V Cokkinos; Ismail Elalamy; Grigoris T Gerotziafas
Journal:  Res Pract Thromb Haemost       Date:  2018-07-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.